Published in J Cheminform on September 24, 2013
ProtDCal: A program to compute general-purpose-numerical descriptors for sequences and 3D-structures of proteins. BMC Bioinformatics (2015) 0.86
Benchmarking of protein descriptor sets in proteochemometric modeling (part 1): comparative study of 13 amino acid descriptor sets. J Cheminform (2013) 0.84
Computational chemogenomics: is it more than inductive transfer? J Comput Aided Mol Des (2014) 0.83
Chemically Aware Model Builder (camb): an R package for property and bioactivity modelling of small molecules. J Cheminform (2015) 0.82
A statistical physics perspective on alignment-independent protein sequence comparison. Bioinformatics (2015) 0.81
Applicability of predictive toxicology methods for monoclonal antibody therapeutics: status Quo and scope. Arch Toxicol (2016) 0.78
Proteochemometric modelling coupled to in silico target prediction: an integrated approach for the simultaneous prediction of polypharmacology and binding affinity/potency of small molecules. J Cheminform (2015) 0.76
Cheminformatics Research at the Unilever Centre for Molecular Science Informatics Cambridge. Mol Inform (2015) 0.75
Unprecedently Large-Scale Kinase Inhibitor Set Enabling the Accurate Prediction of Compound-Kinase Activities: A Way toward Selective Promiscuity by Design? J Chem Inf Model (2016) 0.75
Comparison of the predicted and observed secondary structure of T4 phage lysozyme. Biochim Biophys Acta (1975) 17.03
ChEMBL: a large-scale bioactivity database for drug discovery. Nucleic Acids Res (2011) 14.51
Assessing the accuracy of prediction algorithms for classification: an overview. Bioinformatics (2000) 11.75
Relating protein pharmacology by ligand chemistry. Nat Biotechnol (2007) 6.61
Extended-connectivity fingerprints. J Chem Inf Model (2010) 5.50
JOY: protein sequence-structure representation and analysis. Bioinformatics (1998) 4.10
Update of the drug resistance mutations in HIV-1: March 2013. Top Antivir Med (2013) 3.58
Protein flexibility and drug design: how to hit a moving target. Curr Opin Chem Biol (2002) 2.41
New chemical descriptors relevant for the design of biologically active peptides. A multivariate characterization of 87 amino acids. J Med Chem (1998) 2.29
Neighborhood behavior: a useful concept for validation of "molecular diversity" descriptors. J Med Chem (1996) 1.85
GPCRDB: information system for G protein-coupled receptors. Nucleic Acids Res (2010) 1.77
Peptide quantitative structure-activity relationships, a multivariate approach. J Med Chem (1987) 1.75
How similar are similarity searching methods? A principal component analysis of molecular descriptor space. J Chem Inf Model (2009) 1.69
A chemogenomic analysis of the transmembrane binding cavity of human G-protein-coupled receptors. Proteins (2006) 1.48
PROFEAT: a web server for computing structural and physicochemical features of proteins and peptides from amino acid sequence. Nucleic Acids Res (2006) 1.47
Virtual screen for ligands of orphan G protein-coupled receptors. J Chem Inf Model (2005) 1.28
propy: a tool to generate various modes of Chou's PseAAC. Bioinformatics (2013) 1.25
Development of proteo-chemometrics: a novel technology for the analysis of drug-receptor interactions. Biochim Biophys Acta (2001) 1.19
Virtual screening of GPCRs: an in silico chemogenomics approach. BMC Bioinformatics (2008) 1.17
Proteochemometrics modeling of the interaction of amine G-protein coupled receptors with a diverse set of ligands. Mol Pharmacol (2002) 1.16
A novel chemogenomics analysis of G protein-coupled receptors (GPCRs) and their ligands: a potential strategy for receptor de-orphanization. BMC Bioinformatics (2010) 1.11
A physicogenetic method to assign ligand-binding relationships between 7TM receptors. Bioorg Med Chem Lett (2005) 1.06
Quantitative sequence-activity models (QSAM)--tools for sequence design. Nucleic Acids Res (1993) 1.02
Significantly improved HIV inhibitor efficacy prediction employing proteochemometric models generated from antivirogram data. PLoS Comput Biol (2013) 1.01
Minimum analogue peptide sets (MAPS) for quantitative structure-activity relationships. Int J Pept Protein Res (1991) 1.00
Development and validation of a novel protein-ligand fingerprint to mine chemogenomic space: application to G protein-coupled receptors and their ligands. J Chem Inf Model (2009) 0.99
A new set of amino acid descriptors and its application in peptide QSARs. Biopolymers (2005) 0.99
Generalized modeling of enzyme-ligand interactions using proteochemometrics and local protein substructures. Proteins (2006) 0.98
Proteochemometric modeling of HIV protease susceptibility. BMC Bioinformatics (2008) 0.97
A look inside HIV resistance through retroviral protease interaction maps. PLoS Comput Biol (2007) 0.96
Protein-ligand-based pharmacophores: generation and utility assessment in computational ligand profiling. J Chem Inf Model (2012) 0.96
Proteochemometric modeling of drug resistance over the mutational space for multiple HIV protease variants and multiple protease inhibitors. J Chem Inf Model (2009) 0.96
Structure-based identification of OATP1B1/3 inhibitors. Mol Pharmacol (2013) 0.96
Amino acid side chain descriptors for quantitative structure-activity relationship studies of peptide analogues. J Med Chem (1995) 0.93
Interaction model based on local protein substructures generalizes to the entire structural enzyme-ligand space. J Chem Inf Model (2008) 0.92
Comparison of confirmed inactive and randomly selected compounds as negative training examples in support vector machine-based virtual screening. J Chem Inf Model (2013) 0.92
Chemogenomics approaches for receptor deorphanization and extensions of the chemogenomics concept to phenotypic space. Curr Top Med Chem (2011) 0.92
Interpretable numerical descriptors of amino acid space. J Comput Biol (2009) 0.92
Identifying novel adenosine receptor ligands by simultaneous proteochemometric modeling of rat and human bioactivity data. J Med Chem (2012) 0.90
Prediction of indirect interactions in proteins. BMC Bioinformatics (2006) 0.89
Which compound to select in lead optimization? Prospectively validated proteochemometric models guide preclinical development. PLoS One (2011) 0.88
Kinome-wide interaction modelling using alignment-based and alignment-independent approaches for kinase description and linear and non-linear data analysis techniques. BMC Bioinformatics (2010) 0.88
A structural chemogenomics analysis of aminergic GPCRs: lessons for histamine receptor ligand design. Br J Pharmacol (2013) 0.88
Gaussian process: an alternative approach for QSAM modeling of peptides. Amino Acids (2009) 0.87
Genome-scale screening of drug-target associations relevant to Ki using a chemogenomics approach. PLoS One (2013) 0.86
A ligand's-eye view of protein similarity. Nat Methods (2013) 0.86
ST-scale as a novel amino acid descriptor and its application in QSAM of peptides and analogues. Amino Acids (2009) 0.85
Benchmarking of protein descriptor sets in proteochemometric modeling (part 1): comparative study of 13 amino acid descriptor sets. J Cheminform (2013) 0.84
Melanocortin receptors: ligands and proteochemometrics modeling. Ann N Y Acad Sci (2003) 0.83
Small and colorful stones make beautiful mosaics: fragment-based chemogenomics. Drug Discov Today (2012) 0.82
Mining protein dynamics from sets of crystal structures using "consensus structures". Protein Sci (2010) 0.81
Proteochemometrics mapping of the interaction space for retroviral proteases and their substrates. Bioorg Med Chem (2009) 0.80
ChEMBL: a large-scale bioactivity database for drug discovery. Nucleic Acids Res (2011) 14.51
The 2.6 angstrom crystal structure of a human A2A adenosine receptor bound to an antagonist. Science (2008) 11.74
The genome of the blood fluke Schistosoma mansoni. Nature (2009) 5.94
The ChEMBL bioactivity database: an update. Nucleic Acids Res (2013) 5.41
Integrating high-content screening and ligand-target prediction to identify mechanism of action. Nat Chem Biol (2007) 3.17
Genomic-scale prioritization of drug targets: the TDR Targets database. Nat Rev Drug Discov (2008) 2.58
UniChem: a unified chemical structure cross-referencing and identifier tracking system. J Cheminform (2013) 2.23
Single-cell expression profiling of dopaminergic neurons combined with association analysis identifies pyridoxal kinase as Parkinson's disease gene. Ann Neurol (2009) 2.21
Can we rationally design promiscuous drugs? Curr Opin Struct Biol (2006) 2.06
Multi-parameter phenotypic profiling: using cellular effects to characterize small-molecule compounds. Nat Rev Drug Discov (2009) 1.95
An efficient, versatile and scalable pattern growth approach to mine frequent patterns in unaligned protein sequences. Bioinformatics (2007) 1.92
Structure-based discovery of novel chemotypes for adenosine A(2A) receptor antagonists. J Med Chem (2010) 1.88
2-Amino-6-furan-2-yl-4-substituted nicotinonitriles as A2A adenosine receptor antagonists. J Med Chem (2008) 1.87
Mapping adverse drug reactions in chemical space. J Med Chem (2009) 1.77
Ligand-target prediction using Winnow and naive Bayesian algorithms and the implications of overall performance statistics. J Chem Inf Model (2008) 1.69
Online chemical modeling environment (OCHEM): web platform for data storage, model development and publishing of chemical information. J Comput Aided Mol Des (2011) 1.68
A pharmacological model for psychosis based on N-methyl-D-aspartate receptor hypofunction: molecular, cellular, functional and behavioral abnormalities. Biol Psychiatry (2006) 1.57
A multiplex real-time PCR method to detect and quantify mitochondrial DNA deletions in individual cells. Anal Biochem (2007) 1.56
Multi-RELIEF: a method to recognize specificity determining residues from multiple sequence alignments using a Machine-Learning approach for feature weighting. Bioinformatics (2007) 1.51
Nature of mitochondrial DNA deletions in substantia nigra neurons. Am J Hum Genet (2008) 1.48
Anti-MRSA agent discovery using diversity-oriented synthesis. Angew Chem Int Ed Engl (2008) 1.47
Prioritizing the proteome: identifying pharmaceutically relevant targets. Drug Discov Today (2002) 1.44
Gaining insight into off-target mediated effects of drug candidates with a comprehensive systems chemical biology analysis. J Chem Inf Model (2009) 1.40
Diversity-oriented synthesis; a spectrum of approaches and results. Org Biomol Chem (2008) 1.37
Ligand binding and subtype selectivity of the human A(2A) adenosine receptor: identification and characterization of essential amino acid residues. J Biol Chem (2010) 1.37
From in silico target prediction to multi-target drug design: current databases, methods and applications. J Proteomics (2011) 1.35
Understanding and classifying metabolite space and metabolite-likeness. PLoS One (2011) 1.29
Computational prediction of metabolism: sites, products, SAR, P450 enzyme dynamics, and mechanisms. J Chem Inf Model (2012) 1.29
Recognizing pitfalls in virtual screening: a critical review. J Chem Inf Model (2012) 1.27
G protein-coupled receptor heteromerization: a role in allosteric modulation of ligand binding. Mol Pharmacol (2011) 1.27
Circular fingerprints: flexible molecular descriptors with applications from physical chemistry to ADME. IDrugs (2006) 1.25
Bridging chemical and biological space: "target fishing" using 2D and 3D molecular descriptors. J Med Chem (2006) 1.23
Internalization and desensitization of adenosine receptors. Purinergic Signal (2007) 1.21
Modeling promiscuity based on in vitro safety pharmacology profiling data. ChemMedChem (2007) 1.21
Skeletal diversity construction via a branching synthetic strategy. Chem Commun (Camb) (2006) 1.12
In silico target predictions: defining a benchmarking data set and comparison of performance of the multiclass Naïve Bayes and Parzen-Rosenblatt window. J Chem Inf Model (2013) 1.12
A novel chemogenomics analysis of G protein-coupled receptors (GPCRs) and their ligands: a potential strategy for receptor de-orphanization. BMC Bioinformatics (2010) 1.11
Coupling of the human A1 adenosine receptor to different heterotrimeric G proteins: evidence for agonist-specific G protein activation. Br J Pharmacol (2004) 1.09
Adenosine A1 receptor binding activity of methoxy flavonoids from Orthosiphon stamineus. Planta Med (2009) 1.08
A two-entropies analysis to identify functional positions in the transmembrane region of class A G protein-coupled receptors. Proteins (2006) 1.07
Structure-activity relationships of inverse agonists for G-protein-coupled receptors. Med Res Rev (2005) 1.07
Drip, ship, and retrieve: cooperative recanalization therapy in acute basilar artery occlusion. Stroke (2010) 1.07
Alterations of hippocampal and prefrontal GABAergic interneurons in an animal model of psychosis induced by NMDA receptor antagonism. Schizophr Res (2007) 1.07
Rehabilitation outcome of anoxic-ischaemic encephalopathy survivors with prolonged disorders of consciousness. Resuscitation (2013) 1.06
Mapping small molecule binding data to structural domains. BMC Bioinformatics (2012) 1.05
PDBLIG: classification of small molecular protein binding in the Protein Data Bank. J Med Chem (2004) 1.04
G protein-coupled receptors of the hypothalamic-pituitary-gonadal axis: a case for Gnrh, LH, FSH, and GPR54 receptor ligands. Med Res Rev (2008) 1.03
Random forest Gini importance favours SNPs with large minor allele frequency: impact, sources and recommendations. Brief Bioinform (2011) 1.03
Synthesis and biological evaluation of a new series of 2,3,5-substituted [1,2,4]-thiadiazoles as modulators of adenosine A1 receptors and their molecular mechanism of action. J Med Chem (2005) 1.02
2,4,6-trisubstituted pyrimidines as a new class of selective adenosine A1 receptor antagonists. J Med Chem (2004) 1.02
Characterization of activity landscapes using 2D and 3D similarity methods: consensus activity cliffs. J Chem Inf Model (2009) 1.02
Allosteric modulation of the adenosine family of receptors. Mini Rev Med Chem (2005) 1.02
Expression analysis of dopaminergic neurons in Parkinson's disease and aging links transcriptional dysregulation of energy metabolism to cell death. Acta Neuropathol (2011) 1.01
Significantly improved HIV inhibitor efficacy prediction employing proteochemometric models generated from antivirogram data. PLoS Comput Biol (2013) 1.01
Target prediction for an open access set of compounds active against Mycobacterium tuberculosis. PLoS Comput Biol (2013) 1.01
Global analysis of small molecule binding to related protein targets. PLoS Comput Biol (2012) 0.99
Functionally biased modulation of A(3) adenosine receptor agonist efficacy and potency by imidazoquinolinamine allosteric enhancers. Biochem Pharmacol (2011) 0.99
Annotating Human P-Glycoprotein Bioassay Data. Mol Inform (2012) 0.98
Fishing the target of antitubercular compounds: in silico target deconvolution model development and validation. J Proteome Res (2009) 0.98
Nutritional screening for risk prediction in patients scheduled for extra-abdominal surgery. Nutrition (2013) 0.98
Nicotinic acid receptor subtypes and their ligands. Med Res Rev (2007) 0.98
Determination of different putative allosteric binding pockets at the lutropin receptor by using diverse drug-like low molecular weight ligands. Mol Cell Endocrinol (2012) 0.97
P-glycoprotein substrate models using support vector machines based on a comprehensive data set. J Chem Inf Model (2011) 0.97
Flexible modulation of agonist efficacy at the human A3 adenosine receptor by the imidazoquinoline allosteric enhancer LUF6000. BMC Pharmacol (2008) 0.97
How diverse are diversity assessment methods? A comparative analysis and benchmarking of molecular descriptor space. J Chem Inf Model (2013) 0.97
Bilateral loss of cortical SSEP responses is compatible with good outcome after cardiac arrest. J Neurol (2012) 0.97
Understanding false positives in reporter gene assays: in silico chemogenomics approaches to prioritize cell-based HTS data. J Chem Inf Model (2007) 0.96
General melting point prediction based on a diverse compound data set and artificial neural networks. J Chem Inf Model (2005) 0.96
Structure-based identification of OATP1B1/3 inhibitors. Mol Pharmacol (2013) 0.96
The role of a sodium ion binding site in the allosteric modulation of the A(2A) adenosine G protein-coupled receptor. Structure (2013) 0.95
Grasping premanifest Huntington's disease - shaping new endpoints for new trials. Mov Disord (2010) 0.95
myChEMBL: a virtual machine implementation of open data and cheminformatics tools. Bioinformatics (2013) 0.95
Structure-activity relationships of new 1H-imidazo[4,5-c]quinolin-4-amine derivatives as allosteric enhancers of the A3 adenosine receptor. J Med Chem (2006) 0.94
Collation and data-mining of literature bioactivity data for drug discovery. Biochem Soc Trans (2011) 0.94
Diversity-oriented synthesis of macrocyclic peptidomimetics. Proc Natl Acad Sci U S A (2011) 0.94
Alpha shapes applied to molecular shape characterization exhibit novel properties compared to established shape descriptors. J Chem Inf Model (2009) 0.93
Chemogenomics approaches to rationalizing the mode-of-action of traditional Chinese and Ayurvedic medicines. J Chem Inf Model (2013) 0.93
Systematic, standardized and comprehensive neurological phenotyping of inbred mice strains in the German Mouse Clinic. J Neurosci Methods (2006) 0.92
Chemoinformatics-based classification of prohibited substances employed for doping in sport. J Chem Inf Model (2006) 0.92
Chemogenomics approaches for receptor deorphanization and extensions of the chemogenomics concept to phenotypic space. Curr Top Med Chem (2011) 0.92
The crystallographic structure of the human adenosine A2A receptor in a high-affinity antagonist-bound state: implications for GPCR drug screening and design. Curr Opin Struct Biol (2010) 0.92
Substructure mining using elaborate chemical representation. J Chem Inf Model (2006) 0.92
Support vector inductive logic programming outperforms the naive Bayes classifier and inductive logic programming for the classification of bioactive chemical compounds. J Comput Aided Mol Des (2007) 0.92
Rapid analysis of pharmacology for infectious diseases. Curr Top Med Chem (2011) 0.92
Molecular query language (MQL)--a context-free grammar for substructure matching. J Chem Inf Model (2007) 0.91
GPCR structure and activation: an essential role for the first extracellular loop in activating the adenosine A2B receptor. FASEB J (2010) 0.91
Dual-point competition association assay: a fast and high-throughput kinetic screening method for assessing ligand-receptor binding kinetics. J Biomol Screen (2012) 0.90
Identifying novel adenosine receptor ligands by simultaneous proteochemometric modeling of rat and human bioactivity data. J Med Chem (2012) 0.90
Design, synthesis, and biological evaluation of an allosteric inhibitor of HSET that targets cancer cells with supernumerary centrosomes. Chem Biol (2013) 0.90
Assessment of structural diversity in combinatorial synthesis. Curr Opin Chem Biol (2005) 0.90
A large descriptor set and a probabilistic kernel-based classifier significantly improve druglikeness classification. J Chem Inf Model (2007) 0.90
Hybrid ortho/allosteric ligands for the adenosine A(1) receptor. J Med Chem (2010) 0.90
Accumulation of mitochondrial DNA deletions within dopaminergic neurons triggers neuroprotective mechanisms. Brain (2013) 0.90